Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic
Authors
Keywords
Biomarkers, Precision oncology, Biomarkers validity, Pre-analytical factors, Tumor heterogeneity, Molecular pathology
Journal
CELLULAR ONCOLOGY
Volume 38, Issue 1, Pages 39-48
Publisher
Springer Nature
Online
2014-09-03
DOI
10.1007/s13402-014-0192-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
- (2014) Ann E. McCullough et al. BREAST CANCER RESEARCH AND TREATMENT
- Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
- (2013) Frédérique Penault-Llorca et al. BREAST
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
- (2013) Mothaffar F. Rimawi et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications
- (2013) Samuel Peña-Llopis et al. Nature Protocols
- Inferring tumour purity and stromal and immune cell admixture from expression data
- (2013) Kosuke Yoshihara et al. Nature Communications
- PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
- (2012) G C Wishart et al. BRITISH JOURNAL OF CANCER
- Cancer chromosomal instability: therapeutic and diagnostic challenges
- (2012) Nicholas McGranahan et al. EMBO REPORTS
- Non-formalin fixative versus formalin-fixed tissue: A comparison of histology and RNA quality
- (2012) Daniel Groelz et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Concordance and Discordance in Tumor Genomic Profiling
- (2012) Levi A. Garraway JOURNAL OF CLINICAL ONCOLOGY
- Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
- (2012) Efsevia Vakiani et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues
- (2012) V. M. Neumeister et al. JNCI-Journal of the National Cancer Institute
- Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry
- (2012) Bryce P Portier et al. MODERN PATHOLOGY
- EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
- (2012) Z.-Y. Chen et al. ONCOLOGIST
- Delay to Formalin Fixation Alters Morphology and Immunohistochemistry for Breast Carcinoma
- (2012) Thaer Khoury APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment
- (2011) C. Xiao et al. ANNALS OF ONCOLOGY
- Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
- (2011) Caterina Marchiò et al. BMC Medicine
- PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression
- (2011) Kevin Kalinsky et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
- (2011) A. Fabi et al. CLINICAL CANCER RESEARCH
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Hybrid Capture and Next-Generation Sequencing Identify Viral Integration Sites from Formalin-Fixed, Paraffin-Embedded Tissue
- (2011) Eric J. Duncavage et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables
- (2011) Yalai Bai et al. LABORATORY INVESTIGATION
- Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
- (2011) Sherene Loi et al. LANCET ONCOLOGY
- Do all lung adenocarcinomas follow a stepwise progression?
- (2011) Yasushi Yatabe et al. LUNG CANCER
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
- (2011) Silvia Querings et al. PLoS One
- PIK3CA Mutations in In situ and Invasive Breast Carcinomas
- (2010) A. Miron et al. CANCER RESEARCH
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Genetic variegation of clonal architecture and propagating cells in leukaemia
- (2010) Kristina Anderson et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of biospecimens handling on biomarker research in breast cancer
- (2009) Loris De Cecco et al. BMC CANCER
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
- (2009) Steven M Teutsch et al. GENETICS IN MEDICINE
- Sources of Bias in Specimens for Research About Molecular Markers for Cancer
- (2009) David F. Ransohoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis
- (2009) Michal R. Schweiger et al. PLoS One
- Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability
- (2009) Virginia Espina et al. Proteomics Clinical Applications
- Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour–stroma interactions
- (2008) Chitranjan J. Shukla et al. BJU INTERNATIONAL
- HER-2/neu expression in primary and metastatic breast cancer
- (2008) Elyse E. Lower et al. BREAST CANCER RESEARCH AND TREATMENT
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers
- (2008) E. P. Diamandis et al. CLINICAL CHEMISTRY
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements
- (2008) C. M. Sturgeon et al. CLINICAL CHEMISTRY
- Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials
- (2008) Brian R. Leyland-Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of kinase inhibitor resistance mechanisms in GIST
- (2008) B Liegl et al. JOURNAL OF PATHOLOGY
- A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process
- (2008) Virginia Espina et al. MOLECULAR & CELLULAR PROTEOMICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started